The European Medicines Agency says it is reviewing anemia drugs from Amgen, Roche Holding and Shire PLC to see if they increase the risk of heart and cancer problems. In the meantime, the agency recommended confining the drugs to their indicated use, for treating anemia. The agency says it also is cooperating on a review of Johnson & Johnson's Eprex, sold as Procrit in the U.S.

Full Story:

Related Summaries